Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT03379311 Completed - Clinical trials for Vernal Keratoconjunctivitis

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

KRONOS
Start date: February 26, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.

NCT ID: NCT02970799 Completed - Dry Eye Clinical Trials

Tear Production by Nasal Neurostimulation Compared to Active Control

Start date: August 31, 2016
Phase: N/A
Study type: Interventional

This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones Schirmer test in participants with dry eye disease.

NCT ID: NCT02845674 Completed - Clinical trials for Keratoconjunctivitis Sicca

An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Start date: July 29, 2016
Phase: Phase 3
Study type: Interventional

This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)

NCT ID: NCT02819284 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

STRIDE 2
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02813265 Completed - Dry Eye Syndromes Clinical Trials

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

STRIDE 1
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT02798289 Completed - Dry Eye Syndrome Clinical Trials

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

Start date: June 2016
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in participants with dry eye.

NCT ID: NCT02688556 Completed - Clinical trials for Keratoconjunctivitis Sicca

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

Emerald
Start date: February 2016
Phase: Phase 3
Study type: Interventional

This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis sicca to be conducted at approximately 50 sites.

NCT ID: NCT02680158 Completed - Dry Eye Syndrome Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

Start date: January 31, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.

NCT ID: NCT02665234 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease

Start date: January 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.

NCT ID: NCT02634853 Completed - Clinical trials for Keratoconjunctivitis Sicca

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Start date: December 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.